Nature Communications (May 2021)
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
- Elizabeth M. Swisher,
- Tanya T. Kwan,
- Amit M. Oza,
- Anna V. Tinker,
- Isabelle Ray-Coquard,
- Ana Oaknin,
- Robert L. Coleman,
- Carol Aghajanian,
- Gottfried E. Konecny,
- David M. O’Malley,
- Alexandra Leary,
- Diane Provencher,
- Stephen Welch,
- Lee-may Chen,
- Andrea E. Wahner Hendrickson,
- Ling Ma,
- Prafull Ghatage,
- Rebecca S. Kristeleit,
- Oliver Dorigo,
- Ashan Musafer,
- Scott H. Kaufmann,
- Julia A. Elvin,
- Douglas I. Lin,
- Setsuko K. Chambers,
- Erin Dominy,
- Lan-Thanh Vo,
- Sandra Goble,
- Lara Maloney,
- Heidi Giordano,
- Thomas Harding,
- Alexander Dobrovic,
- Clare L. Scott,
- Kevin K. Lin,
- Iain A. McNeish
Affiliations
- Elizabeth M. Swisher
- University of Washington
- Tanya T. Kwan
- Clovis Oncology, Inc.
- Amit M. Oza
- Princess Margaret Cancer Centre, University Health Network
- Anna V. Tinker
- BC Cancer—Vancouver
- Isabelle Ray-Coquard
- GINECO, Centre Léon Bérard and University Claude Bernard
- Ana Oaknin
- Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO)
- Robert L. Coleman
- The University of Texas, MD Anderson Cancer Center
- Carol Aghajanian
- Memorial Sloan Kettering Cancer Center
- Gottfried E. Konecny
- University of California Los Angeles
- David M. O’Malley
- The Ohio State University, James Cancer Center
- Alexandra Leary
- Gustave Roussy Cancer Center and INSERM U981
- Diane Provencher
- l’Université de Montréal (CHUM)
- Stephen Welch
- Lawson Health Research Institute
- Lee-may Chen
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center
- Andrea E. Wahner Hendrickson
- Mayo Clinic
- Ling Ma
- Rocky Mountain Cancer Centers
- Prafull Ghatage
- Tom Baker Cancer Center
- Rebecca S. Kristeleit
- Guy’s and St. Thomas NHS Foundation Trust
- Oliver Dorigo
- Stanford University Cancer Center and Stanford Cancer Institute
- Ashan Musafer
- University of Melbourne Department of Surgery, Austin Hospital
- Scott H. Kaufmann
- Mayo Clinic
- Julia A. Elvin
- Foundation Medicine, Inc.
- Douglas I. Lin
- Foundation Medicine, Inc.
- Setsuko K. Chambers
- University of Arizona Cancer Center
- Erin Dominy
- Clovis Oncology, Inc.
- Lan-Thanh Vo
- Clovis Oncology, Inc.
- Sandra Goble
- Clovis Oncology, Inc.
- Lara Maloney
- Clovis Oncology, Inc.
- Heidi Giordano
- Clovis Oncology, Inc.
- Thomas Harding
- Clovis Oncology, Inc.
- Alexander Dobrovic
- University of Melbourne Department of Surgery, Austin Hospital
- Clare L. Scott
- Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research
- Kevin K. Lin
- Clovis Oncology, Inc.
- Iain A. McNeish
- Imperial College London
- DOI
- https://doi.org/10.1038/s41467-021-22582-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
The identification of biomarkers of response to PARP inhibitors can enable selection of appropriate ovarian cancer patients for treatment. In this study, the authors report clinical results and exploratory biomarker analyses from the ARIEL2 phase 2 clinical trial on the safety and efficacy of the PARP inhibitor rucaparib in patients with recurrent ovarian cancers
